Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data-Reference-Cited by-同舟云学术

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data

Published:2017-09-29 Issue:8 Volume:33 Page:e2924
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Blau Jenny E.¹^ORCID,Tella Sri Harsha¹^ORCID,Taylor Simeon I.¹²^ORCID,Rother Kristina I.¹^ORCID

Affiliation:

1. Diabetes, Endocrinology, and Obesity Branch, NIDDK; Bethesda MD USA

2. Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine; University of Maryland School of Medicine; Baltimore MD USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference37 articles.

1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

3. Empagliflozin and progression of kidney disease in type 2 diabetes;Wanner;N Engl J Med,2016

4. AstraZeneca Multicenter trial to evaluate the effect of Dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58) 2017 https://clinicaltrials.gov/ct2/show/NCT01730534?term=dapagliflozin+outcome&rank=6

5. Invokana prescribing information www.invokanahcp.com/prescribing-information.pdf

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Euglycemic Diabetic Ketoacidosis Presenting as Hypoglycemia in a Patient With Type 2 Diabetes and Von Gierke’s Disease;Cureus;2024-01-11

2. 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2024;Diabetes Care;2023-12-11

3. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review;Frontiers in Public Health;2023-12-01

4. Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia;Endocrine Practice;2023-12

5. Diabetic Ketoacidosis;Emergency Medicine Clinics of North America;2023-11